PMID- 26027633
OWN - NLM
STAT- MEDLINE
DCOM- 20170412
LR  - 20170412
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 28
IP  - 3
DP  - 2016 Jun
TI  - First evidence of treatment efficacy in metastatic carcinoma of the parotid gland 
      with BRD4/NUT translocation.
PG  - 242-6
LID - 10.1179/1973947815Y.0000000046 [doi]
AB  - BACKGROUND: Nuclear protein in testis (NUT) midline carcinomas (NMC) are 
      characterized by rearrangements of the gene NUT. In the majority of NMCs, a 
      translocation t(15;19), resulting in a BRD4/NUT fusion gene, is present. Nuclear 
      protein in testis midline carcinomas is a rare, but probably underdiagnosed 
      entity due to misdiagnosis. Most cases have been reported in the mediastinum and 
      upper aero-digestive tract. The clinical course of a NMC is extremely aggressive, 
      in spite of intensive chemotherapy and radiotherapy, with an average survival 
      < 1 year. METHODS AND RESULTS: A 32-year-old man presented with a pre-auricular 
      swelling on the left side. After partial parotidectomy, the diagnosis of a NMC 
      was made based on the presence of t(15;19)(q14;p13.1) and BRD4/NUT fusion gene 
      demonstrated by fluorescence in situ hybridization (FISH). During postoperative 
      radiotherapy, the patient developed bone metastases for which chemotherapy 
      consisting of cisplatine, doxorubicine and ifosfamide (PAI) was initiated with 
      remarkable clinical and radiological improvement. Nevertheless, the response was 
      not durable. CONCLUSION: This case illustrates that responses to chemotherapy in 
      the palliative treatment of a t(15;19)-translocated salivary gland carcinoma are 
      possible but not durable.
FAU - Vulsteke, Christof
AU  - Vulsteke C
AD  - a Department of Oncology , Integrated Cancer Center , Ghent , Belgium.
AD  - b Department of General Medical Oncology , UZ Leuven , Belgium.
FAU - Lurquin, Eveline
AU  - Lurquin E
AD  - c Department of Imaging and Pathology , KU Leuven , Belgium.
FAU - Debiec-Rychter, Maria
AU  - Debiec-Rychter M
AD  - d Department of Human Genetics , KU Leuven , Belgium.
FAU - Gheysens, Olivier
AU  - Gheysens O
AD  - c Department of Imaging and Pathology , KU Leuven , Belgium.
FAU - Nuyts, Sandra
AU  - Nuyts S
AD  - e Department of Radiation Oncology , UZ Leuven , Belgium.
AD  - f Department of Oncology , KU Leuven , Belgium.
FAU - Schoenaers, Joseph
AU  - Schoenaers J
AD  - g Department of Oral Health Sciences , KU Leuven , Belgium.
FAU - Politis, Constantinus
AU  - Politis C
AD  - g Department of Oral Health Sciences , KU Leuven , Belgium.
FAU - Mebis, Jeroen
AU  - Mebis J
AD  - h Department of Medical Oncology , Jessa Ziekenhuis , Hasselt , Belgium.
FAU - Hauben, Esther
AU  - Hauben E
AD  - c Department of Imaging and Pathology , KU Leuven , Belgium.
FAU - Clement, Paul M
AU  - Clement PM
AD  - b Department of General Medical Oncology , UZ Leuven , Belgium.
AD  - f Department of Oncology , KU Leuven , Belgium.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (BRD4-NUT fusion oncogene protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 80168379AG (Doxorubicin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - UM20QQM95Y (Ifosfamide)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Neoplasms/*drug therapy/secondary
MH  - Carcinoma/genetics/secondary/*therapy
MH  - Cisplatin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Nuclear Proteins/*genetics
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Parotid Neoplasms/genetics/pathology/*therapy
MH  - Radiotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - BRD4/NUT fusion gene
OT  - Chemotherapy
OT  - Nut midline carcinoma
EDAT- 2015/06/02 06:00
MHDA- 2017/04/13 06:00
CRDT- 2015/06/02 06:00
PHST- 2015/06/02 06:00 [entrez]
PHST- 2015/06/02 06:00 [pubmed]
PHST- 2017/04/13 06:00 [medline]
AID - 10.1179/1973947815Y.0000000046 [doi]
PST - ppublish
SO  - J Chemother. 2016 Jun;28(3):242-6. doi: 10.1179/1973947815Y.0000000046.